Share This Page
Drug Price Trends for ATOVAQUONE-PROGUANIL
✉ Email this page to a colleague
Average Pharmacy Cost for ATOVAQUONE-PROGUANIL
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| ATOVAQUONE-PROGUANIL 250-100 MG TABLET | 66993-0060-27 | 1.49829 | EACH | 2026-03-18 |
| ATOVAQUONE-PROGUANIL 250-100 MG TABLET | 66993-0060-02 | 1.49829 | EACH | 2026-03-18 |
| ATOVAQUONE-PROGUANIL 62.5-25 | 68462-0402-01 | 1.29169 | EACH | 2026-03-18 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for Atovaquone-Proguanil
What is the current market landscape for Atovaquone-Proguanil?
Atovaquone-Proguanil (brand name Malarone) is an antimalarial drug approved for prophylaxis and treatment of malaria caused by Plasmodium falciparum. It is distributed across global markets with a notable presence in countries with endemic malaria, military deployments, and travelers.
Key market participants include GlaxoSmithKline (GSK), which holds the rights to the drug, and generic manufacturers in regions with patent expiration. The drug’s primary competitors are doxycycline, mefloquine, and chloroquine-based therapies.
In 2022, the global malaria prophylaxis market was valued at approximately USD 1 billion, with Atovaquone-Proguanil accounting for about 25%, or USD 250 million of the total revenue (statistics from MarketsandMarkets). Its market share has remained stable owing to its favorable safety profile and high efficacy.
How does patent status influence market dynamics?
The original patent for Atovaquone-Proguanil was filed in the early 2000s and expired in the United States in 2014. As of 2023, patents have lapsed or are nearing expiration in multiple markets, leading to increased generic competition.
Generic versions are priced approximately 30-50% lower than the branded product, which influences market share distribution. In regions where patents have expired, generic formulations dominate sales, reducing GSK's revenue share.
What are the current pricing trends for Atovaquone-Proguanil?
Pricing data reflect regional variations and market maturity:
| Region | Branded Price (per 10-day course) | Generic Price (per 10-day course) | Notes |
|---|---|---|---|
| US | USD 50–70 | USD 15–30 | Branded maintains premium; generics gaining ground |
| Europe | EUR 45–65 | EUR 12–25 | Similar trend; generic uptake increasing |
| Africa | USD 10–20 | USD 5–10 | Price sensitivity critical in endemic areas |
| Southeast Asia | USD 20–35 | USD 8–18 | Market driven by import regulations |
Pricing has stabilized since patent expiration, with tender contracts in Africa and Southeast Asia promoting low-cost generic procurement. The branded drug retains higher pricing in North America and Europe, where supply chain and regulatory controls favor brand loyalty.
What is the forecast for Atovaquone-Proguanil market growth?
Market projections consider evolving malaria incidence, new guidelines, emerging drug resistance, and generics expansion.
Short-term (1–3 years)
- Market volume growth of 2–4% annually, driven by increased travel to endemic regions and military use.
- Price erosion of 15–25% for branded formulations as generics penetrate more markets.
Long-term (4–10 years)
- Potential for the market to plateau or decline by 5–10% annually due to the introduction of new prophylactic agents and vaccine impact.
- Continued generic uptake could reduce branded sales by 40–60%, depending on regional patent status.
Key drivers
- Patent expiration for GSK’s branded product.
- Increased access and subsidy programs in endemic regions.
- New WHO guidelines favoring cost-effective options.
- Resistance development to existing therapies, creating gaps in treatment options.
Risks
- Slow regulatory approval of generics or biosimilars.
- Resistance emergence diminishing drug efficacy.
- Market saturation in low-incidence regions.
What are the strategic implications for stakeholders?
Pharmaceutical companies should monitor timing for patent cliffs and consider investments in pipeline products similar or superior to Atovaquone-Proguanil. Distributors and governments should prepare for generic market expansion by optimizing procurement policies and ensuring supply chain security.
Investments in R&D focused on combination therapies with longer durations of efficacy or formulations that address resistance could affect future market shares.
Summary of market forecasts
- Value in 2023: USD 250 million (branded + generic)
- Expected compound annual growth rate (CAGR): 1–3% (2023–2026)
- Long-term decline predicted post-2026 due to vaccine impact and new therapies
Key Takeaways
- The branded Atovaquone-Proguanil faces increasing generic competition, sharply lowering prices in multiple markets.
- Patent expirations with regional variation significantly influence pricing and market share.
- Market growth remains modest short-term, with potential decline longer-term due to new prophylactic options.
- Stakeholders should align with patent expiration timelines and emerging market trends to optimize strategies.
FAQs
1. How does patent expiration impact Atovaquone-Proguanil pricing?
It enables generic manufacturers to enter markets, leading to lower prices and increased competition, reducing revenue margins for brand owners.
2. Are there alternative therapies likely to replace Atovaquone-Proguanil?
Yes. Emerging drugs like tafenoquine and newer vaccine candidates may diminish reliance on chemoprophylaxis options.
3. What are the key markets for Atovaquone-Proguanil?
North America, Europe, Africa, and Southeast Asia, with the highest consumption in regions with endemic malaria.
4. Will new resistance patterns affect the market?
Yes. Resistance to atovaquone and proguanil can reduce drug efficacy, prompting shifts to alternative therapies.
5. What role does WHO recommendation play in market outlook?
WHO guidelines influence procurement policies and formulary decisions, affecting demand and market direction.
References
[1] MarketsandMarkets. (2023). Malaria diagnostics and therapeutics market report.
[2] GSK. (2014). Patent filings and expiration dates for Atovaquone-Proguanil.
[3] WHO. (2022). Guidelines for malaria prevention and treatment.
[4] IMS Health. (2022). Global pharmaceutical pricing trends.
[5] Statista. (2023). Malaria market size and forecast.
More… ↓
